ONCOFIRM DIAGNOSTICS — April 1, 2025

Revolutionizing Early Cancer Detection

ONCOFIRM DIAGNOSTICS is transforming the future of cancer screening with next‑generation lateral flow assay (LFA) technology. By integrating advanced nanoparticle engineering, powerful signal‑amplification chemistry, and true multiplex detection, we deliver unmatched sensitivity, accuracy, and speed in rapid cancer diagnostics.

Our platform leverages highly specific Thomsen–Friedenreich (TF) and Gal‑GalNAc antigens—two of the most widely expressed cancer‑associated carbohydrate markers—to enable early, reliable, and accessible cancer detection. Designed for physicians, hospitals, clinics, and research institutions, our tests provide non‑invasive, cost‑effective, and scalable diagnostic solutions.

With enhanced biomarker detection, AI‑driven result interpretation, and improved assay stability, ONCOFIRM is redefining what’s possible in point‑of‑care oncology diagnostics—making precision cancer screening faster, smarter, and more accessible worldwide.

OncoFirm Diagnostics — Cancer Rapid Test Technology

As of April 2025, LFA technology has advanced dramatically. Key innovations include:

1. Nanomaterial‑Enhanced Sensitivity

Gold nanoparticles, carbon nanomaterials, and quantum dots significantly boost signal strength, lower detection limits, and support multiplexing for multi‑analyte detection. Sources: GlobeNewswire, PMC

2. Advanced Signal Amplification

Techniques such as catalytic amplification and SERS (surface‑enhanced Raman scattering) enable detection of extremely low‑abundance biomarkers, expanding LFA use into complex diagnostic applications. Source: GlobeNewswire

3. Multiplex Detection

Modern LFAs can now detect multiple biomarkers in a single test, improving diagnostic precision while reducing sample volume and reagent use. Source: MDPI

4. Digital & Smartphone Integration

Digital readers and smartphone‑based apps turn LFAs into quantitative diagnostic tools, offering objective interpretation, data storage, and remote‑care compatibility. Source: Abingdon Health plc

5. Regulatory Alignment

Harmonization between EU IVDR and U.S. FDA frameworks is streamlining global deployment, improving quality standards, and accelerating market access for LFA‑based diagnostics. Source: DCN Dx

6. Next‑Generation Manufacturing

Innovations such as 3D‑printer‑controlled syringe pumps enable precise reagent dispensing, improving consistency, scalability, and production efficiency. Source: arXiv

Together, these advancements are elevating LFAs into high‑performance, user‑friendly diagnostic tools that support point‑of‑care testing across medical, environmental, and research applications.

Investor Relations

For the latest investor updates, contact: Investor@oncofirmdiagnostics.com